Analystreport

GlaxoSmithKline PLC (NYSE: GSK) had its "buy" rating re-affirmed by analysts at Argus. They now have a $50.00 price target on the stock.

GSK plc American Depositary Shares (Each representing two Ordinary Shares)  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors